Novo Nordisk's Rybelsus Gets EU Label Update for Cardiovascular Benefits.

Novo Nordisk has received EU approval to update the label for Rybelsus, an oral GLP-1 receptor agonist, to include cardiovascular benefits demonstrated in the SOUL trial. The study showed Rybelsus reduced the risk of major adverse cardiovascular events by 14% compared to placebo in adults with type 2 diabetes and cardiovascular or kidney disease. This makes Rybelsus the first and only oral GLP-1 receptor agonist available in the EU proven to improve both blood sugar control and cardiovascular outcomes.

Novo Nordisk, a Danish pharmaceutical company, has received approval from the European Medicines Agency (EMA) to update the label for its oral semaglutide medication, Rybelsus®. The update reflects the cardiovascular benefits demonstrated in the clinical SOUL study, making Rybelsus the first and only oral GLP-1 medication in the EU to show efficacy in reducing cardiovascular disease risk Novo Nordisk Receives EMA Approval for Updated Rybelsus Label Highlighting Cardiovascular Benefits^[1].

The SOUL trial, a phase 3b study, demonstrated that Rybelsus reduced the risk of major adverse cardiovascular events, including cardiovascular death, heart attack, and stroke, by 14% compared to placebo in adults with type 2 diabetes and cardiovascular or kidney disease Novo Nordisk Wins EU Label Update For Rybelsus To Include Heart Benefits^[2]. The study also showed a significant reduction in hospitalizations related to serious adverse events.

This update to the Rybelsus label marks a significant advancement in diabetes treatment. It not only improves blood sugar control but also offers proven cardiovascular benefits, providing a comprehensive solution for patients with type 2 diabetes and associated risks. The approval comes ahead of the U.S. decision on a similar label extension, which is expected later this year.

Novo Nordisk's stock, currently trading at $55.90 on the New York Stock Exchange, has seen an increase of $1.03 or 1.87% since the announcement Novo Nordisk Wins EU Label Update For Rybelsus To Include Heart Benefits^[2].